Predictive Technology Group Inc (PRED)

[Regenerative]

There are plenty of other companies selling product so the field is competitive. As an example some providers are switching to using pure exosome products which PB does not offer. For others they feel the product they are using is superior to PB, such as Signature Biologics, Direct Biologics, Kimera, etc. Pricing is an issue and some companies don’t penalize clinics if they buy less versus buying more. I know in my small group of providers pricing is an issue. Another issue is some of the points raised in the Hindenburg hit piece especially the information claiming changing the characterization report of the product.